# A Study of Bimagrumab in Participants With HFpEF

Study · id `cardio:ct-nct07920887` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07920887](<https://clinicaltrials.gov/study/NCT07920887>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07920887

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 540 participants.

## Technical summary

Registry record NCT07920887. Randomized; double masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2029-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 540 participants (planned count; ClinicalTrials.gov record NCT07920887, source copy `cardio:ctgov-nct07920887-2026-11-06`, retrieved 2026-11-18)
- Planned start: 2026-11 (anticipated) (ClinicalTrials.gov record NCT07920887, source copy `cardio:ctgov-nct07920887-2026-11-06`, retrieved 2026-11-18)
- Primary completion: 2029-07 (anticipated) (ClinicalTrials.gov record NCT07920887, source copy `cardio:ctgov-nct07920887-2026-11-06`, retrieved 2026-11-18)
- Completion: 2029-11 (anticipated) (ClinicalTrials.gov record NCT07920887, source copy `cardio:ctgov-nct07920887-2026-11-06`, retrieved 2026-11-18)
- Countries: United States; Hungary; Italy; Poland (ClinicalTrials.gov record NCT07920887, source copy `cardio:ctgov-nct07920887-2026-11-06`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07920887-2026-11-06`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study of Bimagrumab in Participants With HFpEF
- Acronym: ACTIVATE-HFpEF
- Condition: Heart Failure, Diastolic
- Condition: Diastolic Heart Failure
- Condition: Heart Failure, Normal Ejection Fraction
- Condition: Heart Failure, Preserved Ejection Fraction
- Intervention (Drug): Bimagrumab
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with mildly reduced or preserved ejection fraction (`cardio:hfpef`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 3f7a83be3dd651aecaf6e4520d692a31e28d51a2b5e11b7d5f6691ad834a5670
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
